Phase I trial of ONO 7268MX1 in patients with hepatocellular carcinoma (liver cancer) who are refractory or intolerant to standard therapy.

Trial Profile

Phase I trial of ONO 7268MX1 in patients with hepatocellular carcinoma (liver cancer) who are refractory or intolerant to standard therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs ONO-7268MX1 (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 15 Jul 2016 Status changed from not yet recruiting to completed.
    • 02 Jun 2016 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information JapicCTI121933).
    • 03 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top